
X
NICE broadens approval for AstraZeneca’s severe asthma drug
https://pharmaphorum.com/news/nice-broadens-approval-for-astrazenecas-severe-asthma-drug/
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.